Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Gokhan S. Hotamisligil, M.D., Ph.D.

Title
Institution
Department
Address
Phone
Profile Picture

Biography
education and training
Harvard Medical School, Boston, MAPhDBiological Chemistry and Molecular Pharmacology
Ankara University Medical School, Ankara, TurkeyMDMedicine

Overview
overview
The Hotamisligil Lab at the Sabri Ülker Center studies innate adaptive pathways involved in metabolic health and diseases such as obesity, diabetes, and cardiovascular disease. For the past 25 years, our lab has made important contributions to the burgeoning field of “immunometabolism” or “metaflammation” studying the interactions between metabolic and immune responses as critical drivers of numerous chronic diseases. In the last decade, we have approached immunometabolism in these two paths: organelle homeostasis and lipid metabolism. Using biochemical, genetic, and physiological studies, we aim to find novel pathways and preventive, therapeutic solutions to today’s greatest threats to global human health.
webpage

Research
research activities and funding
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
Most Recent  |  List All
  1. T32DK128781 (HOTAMISLIGIL, GOKHAN S) May 1, 2021 - Apr 30, 2026
    NIH
    Training Program in Molecular Metabolism
    Role: Co-Principal Investigator
  2. R01DK123458 (HOTAMISLIGIL, GOKHAN S) Dec 15, 2019 - Nov 30, 2024
    NIH
    Role of Adipokine FABP4 in Glucoregulation and Counter Regulatory Responses
    Role: Principal Investigator
  3. R01HL148137 (HOTAMISLIGIL, GOKHAN S) Aug 1, 2019 - Jul 31, 2024
    NIH
    Novel pathways controlling macrophage inflammation and resolution in atherosclerosis
    Role: Principal Investigator
  4. R01AI116901 (HOTAMISLIGIL, GOKHAN S) Mar 15, 2015 - Feb 28, 2019
    NIH
    The role of fatty acid binding protein aP2 in the pathogenesis and treatment of asthma
    Role: Principal Investigator
  5. R01HL125753 (HOTAMISLIGIL, GOKHAN S) Nov 15, 2014 - Oct 31, 2018
    NIH
    The role of immunometabolic pathways in atherosclerosis
    Role: Principal Investigator

Bibliographic
selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
Updating...
This operation might take several minutes to complete. Please do not close your browser.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: SPH faculty should contact Faculty Affairs at facultyaffairshsph.harvard.edu.
Hotamisligil's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (420)
Explore
_
Co-Authors (41)
Explore
_
Similar People (59)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
© 2024 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.